XFOR (X4 Pharmaceuticals, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by XFOR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-13 | John Volpone | President | Sell | — | — |
| 2026-08-13 | Adam R Craig | Executive Chairman | Sell | — | — |
| 2026-07-01 | Kelly Gold | Director | A | — | — |
| 2026-07-01 | DAVID KIRSKE | Chief Financial Officer | Sell | — | — |
| 2026-05-13 | DAVID KIRSKE | Chief Financial Officer | Sell | — | — |
| 2026-01-07 | Gary Bridger | Director | A | — | — |
| 2026-01-05 | Murray Stewart | Director | A | — | — |
| 2026-01-05 | Francoise de Craecker | Director | A | — | — |
| 2026-01-05 | MICHAEL S WYZGA | Director | A | — | — |
| 2025-10-31 | DAVID KIRSKE | Chief Financial Officer | A | — | — |
| 2025-10-31 | Adam R Craig | Executive Chairman | A | — | — |
| 2025-10-31 | John Volpone | President | A | — | — |
| 2025-10-27 | Adam R Craig | Executive Chairman | Buy | — | — |
| 2025-08-14 | DAVID KIRSKE | Chief Financial Officer | A | — | — |
| 2025-08-14 | Adam R Craig | Executive Chairman | A | — | — |
| 2025-08-14 | John Volpone | President | A | — | — |
| 2025-07-03 | Natasha Fay Thoren | Chief Legal Officer | A | — | — |
| 2025-06-10 | Keith Woods | Director | A | — | — |
| 2025-06-10 | Francoise de Craecker | Director | A | — | — |
| 2025-06-10 | MICHAEL S WYZGA | Director | A | — | — |
| 2025-06-10 | DAVID W J MCGIRR | Director | A | — | — |
| 2025-06-10 | Gary Bridger | Director | A | — | — |
| 2025-06-10 | Murray Stewart | Director | A | — | — |
| 2025-06-03 | Mark Baldry | Chief Commercial Officer | A | — | — |
| 2025-05-20 | Mark Baldry | Chief Commercial Officer | Buy | — | — |
| 2025-02-14 | Christophe Arbet-Engels | Chief Medical Officer | A | — | — |
| 2025-02-14 | Adam S. Mostafa | Chief Financial Officer | A | — | — |
| 2025-02-14 | Paula Ragan | President and CEO | A | — | — |
| 2025-02-14 | Mary DiBiase | Chief Operating Officer | A | — | — |
| 2025-02-14 | Mark Baldry | Chief Commercial Officer | MIXED | — | — |
| 2025-01-27 | Mark Baldry | Chief Commercial Officer | MIXED | — | — |
| 2025-01-27 | Mary DiBiase | Chief Operating Officer | MIXED | — | — |
| 2025-01-27 | Paula Ragan | President and CEO | MIXED | — | — |
| 2025-01-27 | Adam S. Mostafa | Chief Financial Officer | MIXED | — | — |
| 2025-01-27 | Christophe Arbet-Engels | Chief Medical Officer | MIXED | — | — |
| 2024-11-19 | Paula Ragan | President and CEO | Sell | — | — |
| 2024-10-16 | Paula Ragan | President and CEO | Sell | — | — |
| 2024-10-08 | Paula Ragan | President and CEO | MIXED | — | — |
| 2024-10-08 | Mary DiBiase | Chief Operating Officer | MIXED | — | — |
| 2024-10-08 | Arthur Taveras | Chief Scientific Officer | MIXED | — | — |
| 2024-10-08 | Mark Baldry | Chief Commercial Officer | MIXED | — | — |
| 2024-10-08 | Adam S. Mostafa | Chief Financial Officer | MIXED | — | — |
| 2024-09-11 | Mary DiBiase | Chief Operating Officer | Sell | — | — |
| 2024-06-11 | Keith Woods | Director | A | — | — |
| 2024-06-11 | Gary Bridger | Director | A | — | — |
| 2024-06-11 | William Aliski | Director | A | — | — |
| 2024-06-11 | Alison Frances Lawton | Director | A | — | — |
| 2024-06-11 | Murray Stewart | Director | A | — | — |
| 2024-06-11 | DAVID W J MCGIRR | Director | A | — | — |
| 2024-06-11 | MICHAEL S WYZGA | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Executive Chairman | 328,651 | — |
| — | President | 265,305 | — |
| — | Chief Financial Officer | 167,750 | — |
| — | President and CEO | 111,246 | — |
| — | Chief Operating Officer | 38,033 | — |
| — | Chief Medical Officer | 28,807 | — |
| — | Chief Financial Officer | 28,333 | — |
| — | Chief Commercial Officer | 25,337 | — |
| — | Chief Scientific Officer | 12,934 | — |
| — | Chief Legal Officer | 9,462 | — |
| — | Interim Chief Medical Officer | 7,883 | — |
| — | Director | 6,000 | — |
| — | Director | 5,555 | — |
| — | Chief Legal Officer | 4,838 | — |
| — | Director | 4,722 | — |
| — | Director | 4,722 | — |
| — | Director | 4,722 | — |
| — | Chief Medical Officer | 3,470 | — |
| — | Director | 3,222 | — |
| — | Director | 3,222 | — |
| — | Chief Scientific Officer | 1,403 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the XFOR quote page; the site-wide leaderboard is on the insider transactions hub.